R Squared Ltd Takes $79,000 Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

R Squared Ltd acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 8,410 shares of the biopharmaceutical company’s stock, valued at approximately $79,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. OLD Second National Bank of Aurora purchased a new position in Amicus Therapeutics in the 3rd quarter worth approximately $26,000. Hazlett Burt & Watson Inc. boosted its holdings in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,569 shares during the period. Blue Trust Inc. boosted its holdings in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,831 shares during the period. Arcadia Investment Management Corp MI purchased a new position in Amicus Therapeutics in the 3rd quarter worth approximately $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Amicus Therapeutics in the 3rd quarter worth approximately $55,000.

Amicus Therapeutics Trading Down 0.6 %

Amicus Therapeutics stock opened at $9.58 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of -28.18, a PEG ratio of 1.54 and a beta of 0.62. Amicus Therapeutics, Inc. has a one year low of $8.78 and a one year high of $14.03. The company’s fifty day moving average price is $9.64 and its two-hundred day moving average price is $10.48.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Bank of America upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, Guggenheim upped their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Insider Activity

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.